Zuellig Pharma Acquires Cialis® (Tadalafil) From Lilly In Three Additional Markets In Asia

RunWithRugs · 2026-03-13T20:57:22+00:00

Zuellig Pharma has acquired the rights to Cialis® from Eli Lilly for Hong Kong, Macau, and South Korea, expanding its market reach to 11 Asian countries. This move aims to enhance accessibility for men suffering from erectile dysfunction and aligns with Zuellig's strategy to strengthen its healthcare portfolio.

RunWithRugs

2026-03-13 20:57:22

Geração de resumo em curso

(MENAFN- Media OutReach Newswire) SINGAPORE - Media OutReach Newswire - 12 March 2026 - Zuellig Pharma, a leading healthcare solutions company in Asia, today announced that it has acquired all rights, title, and interest in and to Cialis®(Tadalafil), a leading men’s health product from Eli Lilly and Company (“Lilly”) in Hong Kong, Macau and South Korea.

Following the acquisition, Zuellig Pharma will now own the trademarks, marketing authorizations and license manufacturing know-how for Cialis®, a treatment for erectile dysfunction (ED) and benign prostatic hyperplasia (BPH), in 11 markets in Asia, with the expansion of its ownership into three additional markets beyond the original eight. Zuellig Pharma will also continue to promote and distribute the brand in these markets.

The expanded ownership of Cialis® will widen accessibility of the drug to a significant population of men in Asia who are affected by ED and BPH. The acquisition also aligns with Zuellig Pharma’s strategic priority of building a strong portfolio of owned prescription healthcare products as an integrated healthcare solutions company.

“Our acquisition of Cialis® in three additional markets builds on the strong foundation we established two years ago and highlights our proven success in scaling trusted brands effectively through our commercial capabilities and deep expertise. As we broaden our footprint, we remain focused on delivering sustainable growth and advancing our purpose of making in-demand healthcare solutions more accessible to communities in Asia,” said John Graham, CEO of Zuellig Pharma.

MENAFN11032026003551001712ID1110850085

Esta página pode conter conteúdos de terceiros, que são fornecidos apenas para fins informativos (sem representações/garantias) e não devem ser considerados como uma aprovação dos seus pontos de vista pela Gate, nem como aconselhamento financeiro ou profissional. Consulte a Declaração de exoneração de responsabilidade para obter mais informações.